Wow! This is the first wordI think of to describe therecent announcement ofthe early termination of the SystolicBlood Pressure Intervention Trial(SPRINT) sponsored by the NationalInstitutes of Health (NIH). The studybegan in the fall of 2009 and includedmore than 9,300 participants aged50 years and older from about 100medical centers in the United Statesand Puerto Rico. The…
Additional novel medical therapies to treat prostate cancer and earlier use of the existing medical therapies are the future of prostate cancer management.
Advances in prostate cancer screening, management and therapeutics have vastly improved patient care.
No matter how much pharmacologic therapy advances, patient behavior will remain a significant factor in the outcomes achieved.
We may feel good treating a patient’s edema, but is fluid retention always harmful?
For decades, prostate cancer risk (PCa) stratification was based primarily on the architectural pattern of the tumor.
Among the most important challenges in producing a medical newspaper is deciding what studies or topics on which to report.
Eisenhower warned Americans to beware of the “military-industrial complex” as it can overwhelm us.
The separation of continents no longer provides a secure buffer against the spread of communicable diseases from far-flung places.
We crave clinical and scientific data, yet we grieve the performance-based data increasingly directed toward us.
